Abstract
Objective: Maintenance therapy can extend progression-free survival (PFS) in platinum-sensitive recurrent ovarian cancer. Patients with a somatic or germline BRCA mutation have greater clinical benefit with maintenance PARP inhibitor (PARPi) than those with wildtype. Roughly 50% of patients eligible for maintenance therapy do not receive it, and variation in prescribed therapy (bevacizumab [BEV] vs PARPi) exists. Our objective was to analyze institutional utilization of maintenance therapy in platinum-sensitive recurrent ovarian cancer.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
